Form Type: 4

SEC EDGAR Link
Acccession Number:0001209191-19-030060
Date:2019-05-14
Issuer: GENOMIC HEALTH INC (GHDX)
Original Submission Date:

Reporting Person:

COLE G BRADLEY
301 PENOBSCOT DRIVE
REDWOOD CITY, CA 94063

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
COMMON STOCK 2019-05-14 M 5,000 a $17.18 48,722 indirect
COMMON STOCK 2019-05-14 S 1,000 d $56.52 47,722 indirect
COMMON STOCK 2019-05-14 S 4,000 d $57.34 43,722 indirect
COMMON STOCK 2019-05-14 M 6,424 a $22.98 50,146 indirect
COMMON STOCK 2019-05-14 S 1,750 d $56.66 48,396 indirect
COMMON STOCK 2019-05-14 S 4,674 d $57.36 43,722 indirect
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
EMPLOYEE STOCK OPTION (RIGHT TO BUY) 17.18 2019-05-14 deemed execution date M 5,000 (d) 2020-02-18 common stock 5,000 $17.18 11,471 direct
EMPLOYEE STOCK OPTION (RIGHT TO BUY) 22.98 2019-05-14 deemed execution date M 6,424 (d) 2021-01-27 common stock 6,424 $22.98 0 direct
Footnotes
IDfootnote
f1 includes an aggregate of 11,794 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
f2 these sales of common stock were effected pursuant to rule 10b5-1 sales plan adopted by the reporting person on june 4, 2018.
f3 reporting person undertakes to provide upon request by the securities and exchange commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated.
f4 represents weighted average sale price. actual sale prices ranged from $56.01 to $56.95.
f5 represents weighted average sale price. actual sale prices ranged from $57.02 to $57.68.
f6 these sales of common stock were effected pursuant to rule 10b5-1 sales plan adopted by the reporting person on august 23 2018.
f7 represents weighted average sale price. actual sale prices ranged from $56.04 to $57.02.
f8 represents weighted average sale price. actual sale prices ranged from $57.05 to $57.61.
f9 the option became exercisable as to 25% of the shares on february 18, 2011, and became exercisable as to 1/48th of the shares each full month thereafter.
f10 the option became exercisable as to 25% of the shares on january 27, 2012, and became exercisable as to 1/48th of the shares each full month thereafter.

Elevate your investments